Nebivolol/Hydrochlorothiazide Zentiva (Hydrochlorothiazide, Nebivolol)

Nebivolol/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Secondary hypertension: assists in blood‑pressure control when underlying causes contribute to elevated pressure.
• High cardiovascular‑risk patients: helps achieve recommended blood‑pressure goals to lower risk of cardiovascular events.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, while also stimulating endothelial nitric‑oxide release to promote vasodilation. Hydrochlorothiazide acts on the distal convoluted tubule, inhibiting the Na⁺/Cl⁻ cotransporter, which increases urinary sodium and water excretion, leading to reduced plasma volume. The combined actions lower cardiac output and peripheral vascular resistance, resulting in an overall antihypertensive effect.

Nebivolol/Hydrochlorothiazide may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain often occurring early in therapy.
• Fatigue: feeling of tiredness or reduced energy.
• Increased urination: due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Electrolyte disturbances: notably low potassium or sodium levels.
• Acute pancreatitis: inflammation of the pancreas requiring immediate medical attention.
• Allergic reactions: rash, itching, swelling, or difficulty breathing.

Before prescribing Nebivolol/Hydrochlorothiazide, clinicians should consider several safety precautions.

• Blood pressure monitoring: check for excessive hypotension after initiation or dose changes.
• Renal function assessment: evaluate creatinine clearance, especially in patients with chronic kidney disease.
• Electrolyte surveillance: monitor potassium and sodium levels due to diuretic effect.
• Diabetes management: observe for alterations in blood glucose control.
• Avoid abrupt discontinuation: taper to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and light.

Nebivolol/Hydrochlorothiazide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase nebivolol plasma concentrations.
• Lithium: concurrent use can raise lithium levels and risk toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce the diuretic effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (e.g., ACE inhibitors, ARBs): may cause additive blood‑pressure lowering.
• Additional diuretics: increase risk of electrolyte imbalance.
• Beta‑agonists (e.g., albuterol): may diminish bronchodilator response.